AptarGroup (ATR) said late Monday that its proprietary intranasal delivery system is being used in LTR Pharma's Phase II trial of Spontan, an investigational nasal spray for erectile dysfunction.

The Phase II trial, now enrolling its first patients, is assessing the safety, tolerability, and pharmacokinetics of the rapid-acting nasal spray, with Aptar Pharma's multidose system providing precise and consistent dosing, the company said.

The collaboration, supported by Aptar's Nanopharm and Noble subsidiaries, highlights Aptar Pharma's expertise in advancing complex intranasal therapies through formulation, regulatory, and usability support, it added.

Shares of the company were down 2% in after-hours activity.